November 19, 2019 - Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence
October 7, 2019 -Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease
October 3, 2019 -Icosavax Launches with $51 Million Series A Financing to Advance Computationally Designed VLP Vaccines
September 6, 2019 -Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer
September 5, 2019 - Sanofi Ventures co-leads investment in Veralox Therapeutics to enable further develop first-in-class 12-LOX inhibitors for Heparin-Induced Thrombocytopenia and Thrombosis, Type 1 Diabetes, and other indications
July 10, 2019 - Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer
June 27, 2019 - Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome;
Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020
June 26, 2019 -Omada Health Raises $73 Million to Accelerate Program Expansion
Digital Care Leader’s Integrated Program Supports Individuals Dealing with Chronic
Disease, Mental Health Issues
May 15, 2019 -Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases.
April 10 2019 - Inozyme Pharma, a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as the Company’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.
February 5 2019 - Aetion, the health care technology company that delivers the real-world analytics and evidence platform needed to engage in value-based care, announced today a $27 Million Strategic Investment backed by Global Health Care Leaders
January 24 2019 - Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression
January 3 2019 - Click Therapeutics, Inc. and Otsuka America, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder